New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
08:55 EDTADHD, ADHD, ADHDAlcobra management to meet with JMP Securities
Meeting to be held in New York on May 1 hosted by JMP Securities.
News For ADHD From The Last 14 Days
Check below for free stories on ADHD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2014
08:27 EDTADHDAlcobra enrolls first patient in Phase IIb clinical trial
Alcobra announced that the first patient has been enrolled in a Phase IIb study of MDX in adolescents with ADHD. The trial is expected to complete enrollment and report topline data by the end of 2014. The Phase IIb trial is a multi-center, randomized, double-blind, fixed dose study designed to evaluate the safety and tolerability of MDX in up to 82 adolescents with predominantly inattentive ADHD. The primary endpoint will be safety, tolerability and pharmacokinetics.
August 27, 2014
06:25 EDTADHDAlcobra initiated with a Market Perform at FBR Capital
Subscribe for More Information
August 19, 2014
08:05 EDTADHDAlcobra announces enrollment of first patient in Phase IIb clinical trial of MDX
Alcobra announced that the first patient has been enrolled in a Phase IIb Fragile X study of MDX. The FDA granted "Orphan Drug" designation to Metadoxine in the treatment of Fragile X Syndrome in December 2013. The Phase IIb Fragile X trial is a multi-center, randomized, placebo-controlled study and is being conducted in 11 clinical sites, primarily in the U.S. It is designed to investigate MDX for 6 weeks compared with placebo in 60 adolescent and adult subjects with Fragile X Syndrome.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use